A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery

• Drug: azithromycin immediate release (Zithromax)
  
  azithromycin IR 500 mg tablet by mouth for 1 dose
• Other: placebo
  
  placebo
• Drug: azithromycin SR
  
  2.0 g by mouth in the form of liquid for 1 dose

• Experimental: 1
  
  Interventions:
  

  • Drug: azithromycin immediate release (Zithromax)
  • Other: placebo
• Experimental: 2
  
  Interventions:
  

  • Drug: azithromycin SR
  • Other: placebo

Inclusion Criteria:

Inclusion criteria were hospitalized subjects diagnosed with lung cancer that had consented to surgery requiring lung resection who had a life expectancy of >6 months.

Exclusion Criteria:

Key exclusion criteria were antibiotic prophylaxis prior to surgery, diffuse, non-infectious lung disease, history of cigarette smoking of >5 packs per year, patients with any infectious disease that required antibiotic therapy, administration of drugs known to interfere with azithromycin pharmacokinetics, and subjects on chemotherapy.